Nektar Therapeutics
NKTR
$75.06
$2.853.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 21.81M | 11.79M | 11.18M | 10.46M | 29.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.81M | 11.79M | 11.18M | 10.46M | 29.18M |
| Cost of Revenue | -- | -- | -- | -- | 7.98M |
| Gross Profit | 21.81M | 11.79M | 11.18M | 10.46M | 21.20M |
| SG&A Expenses | 11.19M | 16.07M | 17.07M | 24.35M | 17.14M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.90M | 43.32M | 46.96M | 54.83M | 53.86M |
| Operating Income | -19.09M | -31.53M | -35.78M | -44.37M | -24.68M |
| Income Before Tax | -36.05M | -35.56M | -41.78M | -50.83M | 7.00M |
| Income Tax Expenses | 31.00K | -33.00K | -188.00K | 52.00K | -259.00K |
| Earnings from Continuing Operations | -36.08M | -35.52M | -41.59M | -50.88M | 7.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.08M | -35.52M | -41.59M | -50.88M | 7.26M |
| EBIT | -19.09M | -31.53M | -35.78M | -44.37M | -24.68M |
| EBITDA | -18.90M | -31.34M | -35.57M | -43.94M | -24.35M |
| EPS Basic | -1.78 | -1.87 | -2.95 | -3.62 | 0.52 |
| Normalized Basic EPS | -0.85 | -1.17 | -1.83 | -2.25 | -1.43 |
| EPS Diluted | -1.78 | -1.87 | -2.95 | -3.62 | 0.51 |
| Normalized Diluted EPS | -0.85 | -1.17 | -1.83 | -2.25 | -1.41 |
| Average Basic Shares Outstanding | 20.30M | 18.95M | 14.09M | 14.06M | 13.98M |
| Average Diluted Shares Outstanding | 20.30M | 18.95M | 14.09M | 14.06M | 14.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |